P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.

To identify novel inhibitors of transcriptional activation by the HIV Tat protein, we used a combination of in vitro and in vivo Tat-dependent transcription assays to screen >100,000 compounds. All compounds identified blocked Tat-dependent stimulation of transcriptional elongation. Analysis of a panel of structurally diverse inhibitors indicated that their target is the human homolog of Drosophila positive transcription elongation factor b (P-TEFb). Loss of Tat transactivation in extracts depleted of the kinase subunit of human P-TEFb, PITALRE, was reversed by addition of partially purified human P-TEFb. Transfection experiments with wild-type or kinase knockout PITALRE demonstrated that P-TEFb is required for Tat function. Our results suggest that P-TEFb represents an attractive target for the development of novel HIV therapeutics.

[1]  M. Mathews,et al.  Transcription elongation factor P-TEFb is required for HIV-1 tat transactivation in vitro. , 1997, Genes & development.

[2]  R. Gaynor,et al.  Purification of a Tat‐associated kinase reveals a TFIIH complex that modulates HIV‐1 transcription , 1997, The EMBO journal.

[3]  Rage,et al.  RNase Protection Assay , 1996, Methods.

[4]  R. Roeder,et al.  Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain , 1996, Nature.

[5]  D. Price,et al.  Control of RNA Polymerase II Elongation Potential by a Novel Carboxyl-terminal Domain Kinase* , 1996, The Journal of Biological Chemistry.

[6]  P. Sharp,et al.  Tat-SF1: Cofactor for Stimulation of Transcriptional Elongation by HIV-1 Tat , 1996, Science.

[7]  L. Townsend,et al.  Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides. , 1996, Journal of medicinal chemistry.

[8]  M. Dahmus Reversible Phosphorylation of the C-terminal Domain of RNA Polymerase II* , 1996, The Journal of Biological Chemistry.

[9]  D. Bentley,et al.  TFIIH functions in regulating transcriptional elongation by RNA polymerase II in Xenopus oocytes , 1996, Molecular and cellular biology.

[10]  A. Rice,et al.  The human immunodeficiency virus Tat proteins specifically associate with TAK in vivo and require the carboxyl-terminal domain of RNA polymerase II for function , 1996, Journal of virology.

[11]  J. Greenblatt,et al.  Three functional classes of transcriptional activation domain , 1996, Molecular and cellular biology.

[12]  P. Ghazal,et al.  Inhibition of the association of RNA polymerase II with the preinitiation complex by a viral transcriptional repressor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Young,et al.  Keto/enol epoxy steroids as HIV-1 Tat inhibitors: structure-activity relationships and pharmacophore localization. , 1995, Journal of medicinal chemistry.

[14]  A. Rice,et al.  Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor , 1995, Journal of virology.

[15]  M. Groudine,et al.  Promoter-proximal pausing of RNA polymerase II defines a general rate-limiting step after transcription initiation. , 1995, Genes & development.

[16]  P. Sharp,et al.  Novel mechanism and factor for regulation by HIV‐1 Tat. , 1995, The EMBO journal.

[17]  D. Bentley,et al.  Transcriptional elongation by RNA polymerase II is stimulated by transactivators , 1994, Cell.

[18]  R. Tjian,et al.  Transcription factors IIE and IIH and ATP hydrolysis direct promoter clearance by RNA polymerase II , 1994, Cell.

[19]  A. Rice,et al.  Specific interaction of the human immunodeficiency virus Tat proteins with a cellular protein kinase. , 1993, Virology.

[20]  C. F. Kostrub,et al.  RAP30/74 (transcription factor IIF) is required for promoter escape by RNA polymerase II. , 1993, The Journal of biological chemistry.

[21]  D. Trono,et al.  The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent , 1993, Journal of virology.

[22]  J. T. Kadonaga,et al.  In vivo and in vitro analysis of transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins , 1993, Molecular and cellular biology.

[23]  D. Richman,et al.  Discovery and characterization of an HIV-1 Tat antagonist. , 1992, Biochemical Society transactions.

[24]  D. Reinberg,et al.  Factors involved in specific transcription by mammalian RNA polymerase II. Identification and characterization of factor IIH. , 1992, The Journal of biological chemistry.

[25]  R. Tjian,et al.  Structure and functional properties of human general transcription factor IIE , 1991, Nature.

[26]  P. Sharp,et al.  HIV‐1 Tat protein promotes formation of more‐processive elongation complexes. , 1991, The EMBO journal.

[27]  K. Jones,et al.  Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin. , 1991, Genes & Development.

[28]  D. Reinberg,et al.  The nonphosphorylated form of RNA polymerase II preferentially associates with the preinitiation complex. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Reinberg,et al.  Cloning of a human gene encoding the general transcription initiation factor IIB , 1991, Nature.

[30]  D. Baltimore,et al.  The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Mathews,et al.  Synergy between HIV-1 Tat and adenovirus E1A is principally due to stabilization of transcriptional elongation. , 1990, Genes & development.

[32]  I. Sim The Human Immunodeficiency Virus TAT Protein , 1990 .

[33]  Phillip A. Sharp,et al.  HIV-1 Tat protein trans-activates transcription in vitro , 1990, Cell.

[34]  G. Casey,et al.  Human chromosome 12 encodes a species-specific factor which increases human immunodeficiency virus type 1 tat-mediated trans activation in rodent cells , 1990, Journal of virology.

[35]  M. Mathews,et al.  HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation , 1989, Cell.

[36]  P. Sharp,et al.  5,6-Dichloro-1-beta-D-ribofuranosylbenzimidazole inhibits transcription elongation by RNA polymerase II in vitro. , 1989, The Journal of biological chemistry.

[37]  D. Reinberg,et al.  Factors involved in specific transcription in mammalian RNA polymerase II. Functional analysis of initiation factors IIA and IID and identification of a new factor operating at sequences downstream of the initiation site. , 1987, The Journal of biological chemistry.

[38]  R. Weinmann,et al.  Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. , 1986, The Journal of biological chemistry.

[39]  R. Weinmann,et al.  Inhibitory effect of 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole on a protein kinase. , 1984, The Journal of biological chemistry.

[40]  G. Molloy,et al.  Induction of premature termination of transcription of the mouse β-globin gene by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) , 1981 .

[41]  Y. Aloni,et al.  5,6-dichloro-1-beta-ribofuranosylbenzimidazole enhances premature termination of late transcription of simian virus 40 DNA. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[42]  I. Tamm,et al.  Early termination of heterogeneous nuclear RNA transcripts in mammalian cells: accentuation by 5,6-dichloro 1-beta-D-ribofuranosylbenzimidazole. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Darnell,et al.  Multiple discrete sites for premature RNA chain termination late in adenovirus-2 infection: enhancement by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[44]  V. Byrnes,et al.  A system to analyze and identify inhibitors of HIV-1 gene regulation using a defective integrated provirus. , 1996, Methods in enzymology.

[45]  B. Peterlin,et al.  Control of RNA initiation and elongation at the HIV-1 promoter. , 1994, Annual review of biochemistry.